相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn's Disease: A Post Hoc Analysis of the IM-UNITI Trial
Emily C. L. Wong et al.
INFLAMMATORY BOWEL DISEASES (2021)
Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis
Jon T. Giles et al.
RMD OPEN (2021)
DOP61 Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment
G R Lichtenstein et al.
Journal of Crohns & Colitis (2020)
Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis
S. Kurnool et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Body mass index and the risk of infection - from underweight to obesity
J. Dobner et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis
Siddharth Singh et al.
PLOS ONE (2018)
Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes
Siddharth Singh et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
Low muscle mass at initiation of anti-TNF therapy for inflammatory bowel disease is associated with early treatment failure: a retrospective analysis
D. Q. Holt et al.
EUROPEAN JOURNAL OF CLINICAL NUTRITION (2017)
Patients with Crohn's Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab
Loic Guerbau et al.
INFLAMMATORY BOWEL DISEASES (2017)
Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis
Raymond K. Cross
INFLAMMATORY BOWEL DISEASES (2017)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The Intestinal Immune System in Obesity and Insulin Resistance
Daniel A. Winer et al.
CELL METABOLISM (2016)
Weight and Body Composition Compartments do Not Predict Therapeutic Thiopurine Metabolite Levels in Inflammatory Bowel Disease
Darcy Q. Holt et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2016)
The weight of obesity on the human immune response to vaccination
Scott D. Painter et al.
VACCINE (2015)
Body Mass Index Is Associated with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Jie Dong et al.
PLOS ONE (2015)
Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013
Marie Ng et al.
LANCET (2014)
Increased Body Mass Index Is Associated with Earlier Time to Loss of Response to Infliximab in Patients with Inflammatory Bowel Disease
Jason W. Harper et al.
INFLAMMATORY BOWEL DISEASES (2013)
Health-related quality of life in inflammatory bowel disease: Psychosocial, clinical, socioeconomic, and demographic predictors
Anilga Moradkhani et al.
JOURNAL OF CROHNS & COLITIS (2013)
Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review
Natalie A. Molodecky et al.
GASTROENTEROLOGY (2012)
Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease
G. Coteur et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Construct validity of the Short Form-36 Health Survey and its relationship with BMI in obese outpatients
Francesco Corica et al.
OBESITY (2006)
分享论文
